RAPTURE pre-workout recall: check the lot for hidden DMAA
One lot of RAPTURE powder in three flavors is being recalled after FDA testing found the stimulant DMAA. Here are the lot number, UPCs and steps for buyers.
Verified brief
The story in 60 seconds
Leader Formulas recalled lot 260327-4 of RAPTURE Preworkout after FDA testing found undeclared DMAA. The recall covers Rainbow Twist, Electric Lemonade and Berry Mojito sold nationwide online and in stores. Buyers should stop using affected containers and return them for a refund; the company reported no adverse events at the time of its October 6 notice.
This brief and the full story below are based on the disclosed sources. SearchTrends Daily’s interpretation appears later under “Our take.”
Full reporting
The complete story
Leader Formulas of Tomball, Texas, voluntarily recalled one lot of its RAPTURE Preworkout dietary supplement powder on 6 October 2026. The FDA posted the company announcement the next day. FDA testing found 1,3-dimethylamylamine, or DMAA, a stimulant that was not declared on the product label. The company says the affected product reached consumers nationwide through retail outlets and its website between 29 January 2025 and 25 May 2026.
The recall is for lot 260327-4 in 450-gram round plastic containers with red and black lettering and a rhinoceros-print seal. It lists three flavors and UPCs: Rainbow Twist, 710154236506; Electric Lemonade, 710143236513; and Berry Mojito, 710154236544. Check both the lot and the UPC against the FDA notice. The announcement identifies one lot; it does not say that every RAPTURE product has been recalled.
The FDA says DMAA can raise blood pressure and may lead to cardiovascular problems, including chest tightness, shortness of breath or heart attack. This is a risk warning, not a report that these outcomes occurred in the recalled lot. Leader Formulas said it had received no reports of adverse events connected with this recall when it issued its notice. That statement does not establish that every purchaser was reached or that future reports are impossible.
The company says it is notifying distributors and customers and arranging returns. People with an affected container should stop using it and return it to the place of purchase for a full refund. Anyone who believes they have had a problem after taking it should contact a healthcare professional. The FDA also provides its MedWatch system for reporting suspected adverse reactions or product-quality problems.
Image: SearchTrends Daily conceptual editorial illustration created with OpenAI image generation. It does not depict the actual RAPTURE package or an FDA inspection.
Source perspectives
What other reporting adds
These are the reports, official records, and trend observations used to build the story. The note under each link explains exactly what it contributes.
Primary recall announcement: lot, flavors, UPCs, distribution dates, DMAA finding, refund instructions and no adverse-event reports as of notice.
Read original source ↗U.S. Food and Drug AdministrationRAPTURE Preworkout May Be Harmful Due to Hidden IngredientEarlier May 2026 FDA consumer warning after lab analysis found undeclared DMAA.
Read original source ↗SearchTrends Daily opinion
Our take
Analysis
What the evidence and search signal suggest
The public record establishes a specific product, lot and ingredient, but it leaves several questions open: how many containers are still with consumers, how widely the company’s notices have reached them, and whether the recall will expand. The company’s no-adverse-events statement is limited to reports received by 6 October. It should not be read as a clinical safety finding.
This is also a case where the difference between an earlier agency warning and a formal recall matters. The May FDA notice told consumers to avoid the product; the October announcement names the lot and gives purchasers a refund path.
Analysis and commentary are SearchTrends Daily’s interpretation. They are intentionally separated from the sourced account above.
Meaning
Why this matters
The recall concerns a stimulant that buyers may not see on the label. Someone who uses pre-workout powder before exercise could continue taking it without knowing that DMAA is present. The exact lot and flavor details matter: this is a targeted recall, and vague warnings about all supplements would make it harder for owners of the affected containers to act.
The practical step is to compare the container with the FDA listing, stop using a match, and arrange a return. People with symptoms should seek medical advice rather than rely on a news article to assess their health.
Background
How we got here
This recall follows an FDA public warning in May 2026 advising consumers not to buy or use RAPTURE Preworkout after laboratory analysis found undeclared DMAA. The October company announcement converts that warning into a return-and-refund process for one identified lot. The FDA’s general DMAA guidance says it does not consider DMAA a lawful dietary-supplement ingredient and warns about cardiovascular risks, especially alongside other stimulants. The recall notice does not state how much DMAA was found in the affected containers.
Outlook
What is likely to happen next
Leader Formulas says it is arranging returns and notifying distributors and customers. Buyers should use the FDA notice to identify affected containers and follow its refund instructions. The FDA may update its recall record if the scope, status or adverse-event information changes, but no expansion was announced in the sources reviewed. This story will need a further review if the agency or company releases new findings.
A conditional editorial assessment based on the evidence available at the review date, not a guaranteed outcome.
Live record
Updates to this story
No material updates yet.
Commentary
What we think
SearchTrends Daily opinion: The clearest public-service message is the lot number, not the dramatic language that often surrounds supplement recalls. Retailers and the manufacturer should make the three affected UPCs and return instructions prominent wherever the product was sold. The FDA warning existed months before the company recall; that gap makes prompt, direct customer notification especially important.